Ava Willoughby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ava Willoughby has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Allison DePersia
NorthShore University HealthSystem 6
10 shared publications - Amanda Ewart Toland
Department of Cancer Biology and Genetics, Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, USA
10 shared publications - Amy Webb
Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus (A.W.).
10 shared publications - Darcy Thull
University of Pittsburgh 10 Pittsburgh, Pennsylvania
10 shared publications - Doreen M. Agnese
The Ohio State University
10 shared publications - Erika L. Spaeth
Phenogen Sciences Inc, Charlotte, North Carolina, United States of America
10 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- 24 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (9) , 517-528
The Clinical Application of Refined Risk Estimates (caRe) Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Individuals with germline BRCA1 or BRCA2 pathogenic variants (PVs) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates Study is a two-arm randomized controlled trial in women with a BRCA1/BRCA2 PV. The primary objective was to determine whether genotype-informed cancer risk estimates (GRE) compared to standard lifetime cancer risk estimates (SRE) decreased decisional conflict related to cancer risk management decision-making. Women were recruited following disclosure of their PV results. Participants completed a baseline survey and were randomized 1:1 to receive a GRE or SRE. After receiving their results, participants completed a follow-up survey. Likert and continuous data measures were analyzed using linear regression. There were no differences in decisional conflict between study arms at follow-up. However, individuals in the SRE arm showed an increased need for personal structure compared to those in the GRE arm (p =0.02). Compared to baseline, individuals within the SRE arm showed decreased decisional conflict (p =0.003) and increased perceived stress (p =0.02) at follow-up. A more personalized cancer risk estimate did not decrease decisional conflict in women with BRCA1/BRCA2 PVs. Future studies will determine whether a GRE impacts actual decision-making behaviors.
- 24 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 19 (9) , 517-528
The Clinical Application of Refined Risk Estimates (caRe) Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Individuals with germline BRCA1 or BRCA2 pathogenic variants (PVs) may struggle with risk management decision-making. Advancements in technology could provide more specific risk information to patients, but the impact of this information is unknown. The Clinical Application of Refined Risk Estimates Study is a two-arm randomized controlled trial in women with a BRCA1/BRCA2 PV. The primary objective was to determine whether genotype-informed cancer risk estimates (GRE) compared to standard lifetime cancer risk estimates (SRE) decreased decisional conflict related to cancer risk management decision-making. Women were recruited following disclosure of their PV results. Participants completed a baseline survey and were randomized 1:1 to receive a GRE or SRE. After receiving their results, participants completed a follow-up survey. Likert and continuous data measures were analyzed using linear regression. There were no differences in decisional conflict between study arms at follow-up. However, individuals in the SRE arm showed an increased need for personal structure compared to those in the GRE arm (p =0.02). Compared to baseline, individuals within the SRE arm showed decreased decisional conflict (p =0.003) and increased perceived stress (p =0.02) at follow-up. A more personalized cancer risk estimate did not decrease decisional conflict in women with BRCA1/BRCA2 PVs. Future studies will determine whether a GRE impacts actual decision-making behaviors.